Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 17  •  04:00PM ET
22.55
Dollar change
+4.57
Percentage change
25.42
%
Index- P/E- EPS (ttm)-5.24 Insider Own17.94% Shs Outstand40.14M Perf Week12.75%
Market Cap905.16M Forward P/E- EPS next Y-0.34 Insider Trans-0.12% Shs Float32.94M Perf Month67.28%
Enterprise Value851.32M PEG- EPS next Q-0.20 Inst Own33.81% Short Float0.10% Perf Quarter135.20%
Income-125.37M P/S- EPS this Y-60.77% Inst Trans358.12% Short Ratio0.13 Perf Half Y128.93%
Sales0.00M P/B11.67 EPS next Y81.98% ROA-123.18% Short Interest0.03M Perf YTD629.77%
Book/sh1.93 P/C12.96 EPS next 5Y38.85% ROE-234.58% 52W High21.50 4.88% Perf Year531.65%
Cash/sh1.74 P/FCF- EPS past 3/5Y12.94% 24.08% ROIC-210.55% 52W Low2.74 722.99% Perf 3Y65.81%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility11.51% 8.37% Perf 5Y-21.15%
Dividend TTM- EV/Sales- EPS Y/Y TTM1.29% Oper. Margin- ATR (14)1.80 Perf 10Y-93.17%
Dividend Ex-Date- Quick Ratio1.80 Sales Y/Y TTM- Profit Margin- RSI (14)77.97 Recom1.44
Dividend Gr. 3/5Y- - Current Ratio1.80 EPS Q/Q23.95% SMA2045.14% Beta-1.18 Target Price41.13
Payout- Debt/Eq0.30 Sales Q/Q- SMA5048.81% Rel Volume15.76 Prev Close17.98
Employees109 LT Debt/Eq0.13 EarningsOct 28 AMC SMA200116.64% Avg Volume250.03K Price22.55
IPOOct 22, 2014 Option/ShortNo / Yes EPS/Sales Surpr.24.41% 218.80% Trades Volume3,941,054 Change25.42%
Date Action Analyst Rating Change Price Target Change
Dec-15-25Initiated Cantor Fitzgerald Overweight $42
Dec-03-25Initiated Guggenheim Buy $35
May-29-25Resumed Goldman Sell $7.25
Jan-04-23Upgrade Societe Generale Hold → Buy
Dec-16-22Downgrade Goldman Neutral → Sell
May-10-22Downgrade Goldman Buy → Neutral $6 → $1.50
Sep-14-21Upgrade Societe Generale Hold → Buy
Jan-22-21Downgrade Societe Generale Hold → Sell
Nov-02-20Upgrade Societe Generale Sell → Hold
Aug-06-20Downgrade Societe Generale Buy → Sell
Today 04:01PM
08:42AM
07:27AM
Dec-16-25 04:05PM
Dec-15-25 09:16AM
09:15AM Loading…
Dec-03-25 09:15AM
Dec-02-25 04:00PM
Nov-11-25 11:50PM
Nov-04-25 04:30PM
Nov-03-25 04:30PM
04:25PM
Oct-31-25 09:40AM
Oct-30-25 04:30PM
03:00AM
Oct-29-25 06:47PM
04:25PM Loading…
Oct-28-25 04:25PM
Oct-17-25 09:16AM
Oct-06-25 05:02PM
Sep-23-25 05:04AM
Sep-18-25 04:30PM
Sep-05-25 04:30PM
Sep-03-25 04:30PM
Aug-01-25 04:05PM
Jul-29-25 04:17PM
04:08PM
Jul-28-25 04:30PM
Jul-24-25 07:40AM
Jul-22-25 04:30PM
Jul-09-25 07:20AM
Jun-25-25 04:15PM
09:40AM Loading…
Jun-23-25 09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
Jun-12-25 04:05PM
Jun-11-25 04:30PM
Jun-04-25 04:32PM
Jun-03-25 04:30PM
May-21-25 09:40AM
May-16-25 12:00PM
08:50AM
May-15-25 04:30PM
May-06-25 04:30PM
May-05-25 04:30PM
Apr-30-25 04:00PM
08:50AM
06:25AM
Apr-14-25 08:50AM
Apr-11-25 04:30PM
Apr-10-25 07:00AM
Mar-27-25 10:30PM
Mar-24-25 03:09AM
02:30AM
Feb-25-25 04:01PM
Jan-13-25 04:05PM
Jan-08-25 04:05PM
Dec-12-24 09:59AM
Dec-11-24 04:05PM
Dec-02-24 04:30PM
Nov-11-24 04:30PM
Nov-06-24 04:30PM
Oct-24-24 08:31AM
Oct-22-24 04:45PM
Oct-18-24 04:30PM
Oct-14-24 04:30PM
Sep-23-24 04:30PM
Sep-04-24 04:30PM
Aug-02-24 04:30PM
Jul-30-24 08:55PM
05:30PM
04:30PM
Jul-29-24 01:30AM
Jul-08-24 04:30PM
Jun-05-24 04:30PM
Jun-04-24 04:30PM
May-31-24 09:51AM
May-30-24 04:30PM
May-17-24 04:30PM
May-16-24 04:30PM
May-09-24 04:30PM
May-07-24 11:53PM
04:30PM
Apr-25-24 04:30PM
Apr-04-24 04:43PM
Mar-08-24 11:01AM
09:33AM
Mar-07-24 10:52PM
04:30PM
Mar-04-24 04:30PM
Feb-20-24 04:30PM
Jan-16-24 04:30PM
Dec-04-23 04:30PM
Nov-09-23 04:30PM
Nov-06-23 04:30PM
Nov-02-23 04:30PM
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mohideen PharisChief Medical OfficerNov 20 '25Sale2.886,49618,708103,153Nov 25 04:15 PM
Mohideen PharisChief Medical OfficerNov 21 '25Sale2.771,6244,498101,529Nov 25 04:15 PM
Mohideen PharisChief Medical OfficerJul 29 '25Sale2.224641,030109,649Jul 31 04:15 PM
Mohideen PharisChief Medical OfficerMay 22 '25Sale1.84397730110,113May 27 04:10 PM
Mohideen PharisChief Medical OfficerJan 30 '25Sale0.85600510110,510Jan 31 04:59 PM